免疫检查点抑制剂在治疗转移性去势抵抗性前列腺癌中的研究进展
吕泉龙， 史文杰， 孙文国 - 中华诊断学电子杂志, 2024 - zhzdxdzzz.cma-cmc.com.cn
… checkpoint inhibitors in the treatment of metastatic castration-resistant prostate cancer[J]. …
Part II-2020 update:treatment of relapsing and metastatic prostate cancer[J].Eur Urol,2021,…
Part II-2020 update:treatment of relapsing and metastatic prostate cancer[J].Eur Urol,2021,…
177Lu-PSMA靶向治疗转移性去势抵抗性前列腺癌的研究进展
赵艳红， 陈跃 - 国际放射医学核医学杂志, 2019 - ijrmnm.com
… 抵抗性前列腺癌 (castration-resistant prostate cancer,CRPC);… 前列腺癌(metastatic castration
resistant prostate cancer,mCRPC… metastatic castration-resistant prostate cancer: a systematic …
resistant prostate cancer,mCRPC… metastatic castration-resistant prostate cancer: a systematic …
前列腺癌脊柱转移瘤治疗进展
蒋伟刚， 孙薇， 刘耀升， 刘蜀彬 - 中华损伤与修复杂志 …, 2019 - zhssyxfzz.cma-cmc.com.cn
… There is no standard treatment for spinal metastasis of prostate cancer. This paper briefly …
care, bone targeted agents for spinal metastases of prostate cancer. The authors think that the …
care, bone targeted agents for spinal metastases of prostate cancer. The authors think that the …
前列腺癌雄激素剥夺治疗的新思路——睾酮最大控制临床研究新进展
卞晓洁， 叶定伟 - 中国癌症杂志, 2022 - china-oncology.com
… of prostate cancer treatment. For example, in the treatment of castration-resistant prostate
cancer (… part Ⅱ-2020 update: treatment of relapsing and metastatic prostate cancer[J]. Eur Urol, …
cancer (… part Ⅱ-2020 update: treatment of relapsing and metastatic prostate cancer[J]. Eur Urol, …
基于非靶代谢组学揭示恩杂鲁胺耐药的去势抵抗性前列腺癌细胞代谢表型
徐文浩， 王骏， 田熙， 万方宁， 瞿元元， 张海梁… - 临床泌尿外科 …, 2022 - lcmw.whuhzzs.com
… Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic
castration-resistant prostate cancer treated with abiraterone or enzalutamide[J]. Eur J Nucl Med …
castration-resistant prostate cancer treated with abiraterone or enzalutamide[J]. Eur J Nucl Med …
CPCC 晚期前列腺癌中国专家共识——转移性激素敏感性前列腺癌起始应用新型内分泌治疗的全程管理(2022 年版)
…, H Jian, Chinese Prostate Cancer Consortium - 中国癌症 …, 2023 - china-oncology.com
… systemic therapy for mHSPC, in which androgen deprivation … 前列腺癌(metastatic
castration-resistant prostate cancer,mCRPC… objectives for castration-resistant prostate cancer: …
castration-resistant prostate cancer,mCRPC… objectives for castration-resistant prostate cancer: …
雄激素去势治疗联合多西他赛对晚期前列腺癌患者血清hk2, miR-221 及NF-κB 水平的影响.
秦策， 王洋， 吴媛媛， 张冬， 史英… - Progress in Modern …, 2021 - search.ebscohost.com
… Updates in advanced prostate cancer 2018[J]. … for Metastatic Castrationresistant Prostate
Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-…
Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-…
[HTML][HTML] 纯中药治疗雄激素抵抗的复发难治性前列腺癌1 例
杨琴， 熊绍权 - Advances in Clinical Medicine, 2024 - hanspub.org
… for the treatment of castration-resistance relapsed refractory prostate cancer through the
treatment of a case of relapsed refractory prostate cancer by simple traditional Chinese medicine…
treatment of a case of relapsed refractory prostate cancer by simple traditional Chinese medicine…
前列腺特异性膜抗原PET 在前列腺癌诊疗中的研究进展
刘珊， 吕哲昊， 付鹏， 赵长久 - 国际放射医学核医学杂志, 2023 - ijrmnm.com
… This paper reviews the latest research progress of PSMA … 性PCa (metastatic castration-resistant
prostate cancer,mCRPC)… with suspected prostate cancer: a systematic review and meta-…
prostate cancer,mCRPC)… with suspected prostate cancer: a systematic review and meta-…
CPCC 晚期前列腺癌中国专家共识——转移性激素敏感性前列腺癌起始应用新型内分泌治疗的全程管理(2022 年版).
叶定伟， 黄健 - China Oncology, 2022 - search.ebscohost.com
… systemic therapy for mHSPC, in which androgen deprivation … 前列腺癌(metastatic
castration-resistant prostate cancer,mCRPC… objectives for castration-resistant prostate cancer: …
castration-resistant prostate cancer,mCRPC… objectives for castration-resistant prostate cancer: …